Candel Therapeutics Q1 Net Loss $8.9M; Cash $194.8M after Offering
Candel Therapeutics reported a net loss of $8.9 million for the first quarter of 2026, a significant shift from the net income of $7.4 million in the same period last year. Despite the loss, the company substantially strengthened its financial position, with cash and cash equivalents rising to $194.8 million, primarily due to $93.5 million in net proceeds from a public offering of common stock in February 2026. The company continues to incur significant operating losses and expects to require additional funding to finance its operations, but believes existing resources will fund planned operations for at least 12 months.
Key Highlights
- Net loss for Q1 2026 was $8.9 million, compared to net income of $7.4 million for Q1 2025.
- Cash and cash equivalents increased to $194.8 million at March 31, 2026, from $119.7 million at December 31, 2025.
- Received approximately $93.5 million in net proceeds from a public offering of common stock in February 2026.
- Research and development expenses rose to $9.8 million in Q1 2026 from $4.0 million in Q1 2025.
- General and administrative expenses increased to $6.4 million in Q1 2026 from $4.1 million in Q1 2025.
- Accumulated deficit reached $239.2 million as of March 31, 2026.
- Total stockholders' equity increased to $138.0 million at March 31, 2026, from $51.9 million at December 31, 2025.
- Entered into a Loan and Security Agreement (Trinity LSA) in October 2025, drawing down $50.0 million.
Price Impact
More from CADL
Candel Therapeutics Details CFO Charles Schoch's Employment Terms
Candel Therapeutics Phase 3 aglatimagene data shows 39% DFS improvement
Candel Therapeutics Plans Q4 2026 BLA for Prostate Cancer; Q1 Net Loss $8.9M